Augmentation of Blood Dendritic Cells by Extracorporeal Photopheresis in Patients with Leukemic Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease

Shiue, Lisa H.; Alousi, Amin M.; Wei, Caimiao; Hosing, Chitra; Duvic, Madeleine; Ni, Xiao

doi:10.1038/jid.2013.142

Cited by 21 publications

(31 citation statements)

References 11 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…33 It is known that mDCs primarily polarize naïve T cells toward a Th1 phenotype, whereas pDCs primarily result in a Th2/Treg phenotype. 34 Recently, Shiue and colleagues 35 found increased mDC populations, increased mDC/pDC ratios, and upregulation of HLA-DR expression on DCs following ECP in two-thirds of patients with MF and B1/B2 blood stage or SS. Their results suggest that ECP treatment is associated with favorable mDC modulation.…”

Section: Mechanism Of Actionmentioning

confidence: 98%

Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome

Zic

2015

Dermatologic Clinics

View full text Add to dashboard Cite

Extracorporeal photopheresis (ECP) is an immunomodulating procedure that leads to an expansion of peripheral blood dendritic cell populations and an enhanced TH1 immune response in cutaneous T-cell lymphoma (CTCL). Because of its excellent side effect profile and moderate efficacy, ECP is considered first-line therapy for erythrodermic mycosis fungoides (MF) and Sézary syndrome. Patients with a measurable but low blood tumor burden are most likely to respond to ECP, and the addition of adjunctive immunostimulatory agents may also increase response rates. There may be a role for ECP in the treatment of refractory early stage MF, but data are limited.

show abstract

Section: Mechanism Of Actionmentioning

confidence: 98%

Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome

Zic

2015

Dermatologic Clinics

View full text Add to dashboard Cite

show abstract

“…Notably, the pDC population increased following ECP to treat patients that developed GVHD in response to stem cell transplant, indicating that pDCs may promote a favorable tolerogenic outcome (38). …”

Section: Introductionmentioning

confidence: 99%

Plasmacytoid Dendritic Cells Respond Directly to Apoptotic Cells by Secreting Immune Regulatory IL-10 or IFN-α

et al. 2016

View full text Add to dashboard Cite

Plasmacytoid dendritic cells (pDCs) play a pivotal role in driving the autoimmune disease systemic lupus erythematosus, via the secretion of IFN-α in response to nuclear self-antigens complexed with autoantibodies. Apoptotic cells, generated at sites of inflammation or secondary lymphoid organs, are exposed to activated pDCs and also express the same nuclear antigens on their cell surface. Here, we show that in the absence of autoantibodies, activated pDCs directly respond to apoptotic cell-expressed chromatin complexes by secreting IL-10 and IL-6, which also induces T cells to secrete IL-10. Conversely, when activated by the viral mimetic CpG-A, apoptotic cells enhance their secretion of IFN-α. This study demonstrates that activated pDCs respond directly to apoptotic cells and may maintain tolerance via IL-10, or promote inflammation through secretion of IFN-α, depending on the inflammatory context.

show abstract

“…Numerous studies have reported that ECP can expand the number of regulatory T cells (Tregs), providing a rationale to understand the immunoregulatory efficacy of ECP for the treatment of graft-versus-host disease and solid organ transplant rejection (10)(11)(12). In contrast, only few publications have revealed the immunostimulatory activity of ECP, which suggests that ECP promotes monocyte differentiation into dendritic cells (DC) and elevation of TNF-a production (13)(14)(15).…”

mentioning

confidence: 99%

Extracorporeal Photopheresis Promotes IL-1β Production

Yakut

Jakobs

Peric

et al. 2015

The Journal of Immunology

View full text Add to dashboard Cite

Extracorporeal photopheresis (ECP) is a widely used clinical cell-based therapy exhibiting efficacy in heterogenous immune-mediated diseases such as cutaneous T cell lymphoma, graft-versus-host disease, and organ allograft rejection. Despite its documented efficacy in cancer immunotherapy, little is known regarding the induction of immunostimulatory mediators by ECP. In this article, we show that ECP promotes marked release of the prototypic immunostimulatory cytokine IL-1β. ECP primes IL-1β production and activates IL-1β maturation and release in the context of caspase-1 activation in monocytes and myeloid dendritic cells. Of interest, IL-1β maturation by ECP was fully intact in murine cells deficient in caspase-1, suggesting the predominance of an inflammasome-independent pathway for ECP-dependent IL-1β maturation. Clinically, patient analysis revealed significantly increased IL-1β production in stimulated leukapheresis concentrates and peripheral blood samples after ECP. Collectively, these results provide evidence for promotion of IL-1β production by ECP and offer new insight into the immunostimulatory capacity of ECP.

show abstract

Augmentation of Blood Dendritic Cells by Extracorporeal Photopheresis in Patients with Leukemic Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease

Cited by 21 publications

References 11 publications

Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome

Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome

Plasmacytoid Dendritic Cells Respond Directly to Apoptotic Cells by Secreting Immune Regulatory IL-10 or IFN-α

Extracorporeal Photopheresis Promotes IL-1β Production

Contact Info

Product

Resources

About